Alcon Inc is a global leader in the eye care industry, specializing in the development and manufacturing of innovative products aimed at enhancing vision and eye health. The company offers a comprehensive range of surgical and vision care solutions, including advanced intraocular lenses, surgical instruments, contact lenses, and eye care products. With a commitment to improving patient outcomes and quality of life, Alcon employs cutting-edge technology and research to address various eye conditions and promote healthier vision for individuals around the world. Read More
A second day of selling pressure hit technology stocks tied to the AI theme on Wednesday, as sentiment cooled after an MIT report questioned the broad profitability of the new technology.
Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and six month periods ending June 30, 2025. For the second quarter of 2025, sales were $2.6 billion, up 4% on a reported basis and up 3% on a constant currency basis1, as compared to the same quarter of the previous year. Alcon reported diluted earnings per share of $0.35 and core diluted earnings per share2 of $0.76 in the second quarter of 2025.
Having a stock you own get acquired at a premium feels good at first, but what about the long-term gains that will be left behind when your chips are off the table?
BALA CYNWYD, Pa., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
BALA CYNWYD, Pa., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and STAAR Surgical Company (NASDAQ: STAA), the manufacturer of the Implantable Collamer® Lens (ICL), today announced the companies have entered into a definitive merger agreement through which Alcon intends to acquire STAAR. The acquisition includes the EVO family of lenses (EVO ICL™) for vision correction for patients with moderate to high myopia (nearsightedness), with or without astigmatism.
Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced its intention to acquire LumiThera, Inc., a leader in light-based innovations for ophthalmology, and its PBM device for the treatment of early and intermediate dry AMD.1 LumiThera’s PBM is the only device that has demonstrated meaningful vision improvement compared to baseline for people living with early to intermediate dry AMD.2,* Dry AMD is a progressive disease typically treated in late stage, with limited treatment options.2
